首页> 外文OA文献 >Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

【2h】

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

机译：发现新型EGFR配体DPBA，可降解EGFR并抑制EGFR阳性NSCLC生长

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Nan Yao; Chen-Ran Wang; Ming-Qun Liu; Ying-Jie Li; Wei-Min Chen; Zheng-Qiu Li; Qi Qi; Jin-Jian Lu; Chun-Lin Fan; Min-Feng Chen; Ming Qi; Xiao-Bo Li; Jian Hong; Dong-Mei Zhang; Wen-Cai Ye;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth [J] . Nan Yao, Chen-Ran Wang, Ming-Qun Liu, Signal transduction and targeted therapy. . 2020,第1期

机译：发现新型EGFR配体DPBA，可降解EGFR并抑制EGFR阳性NSCLC生长
2. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). [J] . Kollmannsberger C, Schittenhelm M, Honecker F, Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第6期

机译：人源化单克隆抗表皮生长因子受体（EGFR）抗体EMD 72000（matuzumab）与紫杉醇联合用于EGFR阳性晚期非小细胞肺癌（NSCLC）患者的I期研究。
3. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) [J] . C. Kollmannsberger, M. Schittenhelm, F. Honecker, Annals of Oncology . 2006,第6期

机译：人源化单克隆抗表皮生长因子受体（EGFR）抗体EMD 72000（matuzumab）与紫杉醇联合用于EGFR阳性晚期非小细胞肺癌（NSCLC）患者的I期研究
4. PET/CT Radiomic Sequencer for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients [C] . I. Shiri, H. Maleki, G. Hajianfar, IEEE Nuclear Science Symposium;Medical Imaging Conference . 2018

机译：PET / CT放射测序仪可预测NSCLC患者的EGFR和KRAS突变状态
5. Receptor-Mediated Uptake and Intracellular Sorting of Multivalent Lipid Nanoparticles Against the Epidermal Growth Factor Receptor (EGFR) and the Human EGFR 2 (HER2). [D] . Tran, David Tu. 2013

机译：受体介导的对表皮生长因子受体（EGFR）和人类EGFR 2（HER2）的多价脂质纳米颗粒的摄取和细胞内分选。
6. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth [O] . Nan Yao, Chen-Ran Wang, Ming-Qun Liu, 2020

机译：发现新型EGFR配体DPBA可降解EGFR并抑制EGFR阳性NSCLC生长
7. Impact of Programmed Death-Ligand 1 (PD-L1) Expression on The Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) [O] . C.C. Lee, Y.Y. Soon, C.N. Leong, 2020

机译：编程死亡 - 配体1（PD-L1）表达对第一线表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在转移的非小细胞肺癌（NSCLC）中的疗效的影响

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

著录项

引文网络

相似文献

相关主题

期刊订阅